BC
Boxer Capital Portfolio holdings
AUM
$2.04B
1-Year Return
108.35%
This Quarter Return
+26.13%
1 Year Return
+108.35%
3 Year Return
+260.95%
5 Year Return
+1,103.68%
10 Year Return
–
AUM
$2.02B
AUM Growth
+$18.4M
(+0.92%)
Cap. Flow
-$112M
Cap. Flow
% of AUM
-5.51%
Top 10 Holdings %
Top 10 Hldgs %
53.81%
Holding
65
New
13
Increased
7
Reduced
4
Closed
6
Top Buys
| 1 |
Fate Therapeutics
FATE
|
+$56.6M |
| 2 |
Nkarta
NKTX
|
+$45M |
| 3 |
Viking Therapeutics
VKTX
|
+$24.6M |
| 4 |
Kura Oncology
KURA
|
+$21.3M |
| 5 |
Allogene Therapeutics
ALLO
|
+$17.2M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$188M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
+$87.8M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$79.1M |
| 4 |
argenx
ARGX
|
+$23.6M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$9.63M |
Sector Composition
| 1 | Healthcare | 99.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Viking Therapeutics
VKTX
$2.79B
| $24.6M | 1.22% |
+300,000
| New | +$24.6M |
|
27
Oric Pharmaceuticals
ORIC
$1.05B
| $23.8M | 1.18% |
1,732,571
| – | – |
|
|
28
Kura Oncology
KURA
$711M
| $21.3M | 1.05% |
+1,000,000
| New | +$21.3M |
|
29
Geron
GERN
$810M
| $19.8M | 0.98% |
6,000,000
+3,000,000
| +100% | +$9.9M |
|
30
Day One Biopharmaceuticals
DAWN
$729M
| $19.7M | 0.97% |
1,189,943
| – | – |
|
|
THRD
31
DELISTED
Third Harmonic Bio
THRD
| $18.9M | 0.93% |
2,000,000
+1,250,000
| +167% | +$11.8M |
|
32
KalVista Pharmaceuticals
KALV
$708M
| $18.9M | 0.93% |
1,590,000
-60,000
| -4% | -$712K |
|
|
33
Allogene Therapeutics
ALLO
$251M
| $17.2M | 0.85% |
+3,850,000
| New | +$17.2M |
|
34
Structure Therapeutics
GPCR
$1.2B
| $17.1M | 0.85% |
400,000
| – | – |
|
35
Prothena Corp
PRTA
$442M
| $17.1M | 0.84% |
690,000
+25,000
| +4% | +$619K |
|
36
Sana Biotechnology
SANA
$828M
| $15.5M | 0.76% |
+1,545,000
| New | +$15.5M |
|
37
Relay Therapeutics
RLAY
$688M
| $15.1M | 0.75% |
1,819,132
| – | – |
|
|
PSTX
38
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $14.3M | 0.71% |
+4,475,000
| New | +$14.3M |
|
39
enGene Holdings
ENGN
$292M
| $12.3M | 0.61% |
+727,900
| New | +$12.3M |
|
40
Prelude Therapeutics
PRLD
$64M
| $12.2M | 0.6% |
2,568,287
| – | – |
|
41
Enliven Therapeutics
ELVN
$1.18B
| $11.8M | 0.58% |
671,358
+25,300
| +4% | +$445K |
|
|
42
Iovance Biotherapeutics
IOVA
$821M
| $11.1M | 0.55% |
750,000
-650,000
| -46% | -$9.63M |
|
43
Jasper Therapeutics
JSPR
$39.5M
| $10.3M | 0.51% |
+350,000
| New | +$10.3M |
|
|
BOLD
44
Boundless Bio
BOLD
$25.7M
| $10.1M | 0.5% |
+711,329
| New | +$10.1M |
|
45
Spyre Therapeutics
SYRE
$945M
| $9.48M | 0.47% |
250,000
| – | – |
|
46
Century Therapeutics
IPSC
$43.3M
| $7.32M | 0.36% |
+1,750,000
| New | +$7.32M |
|
47
Zentalis Pharmaceuticals
ZNTL
$107M
| $7.09M | 0.35% |
450,000
| – | – |
|
48
Amylyx Pharmaceuticals
AMLX
$1.24B
| $4.26M | 0.21% |
+1,500,000
| New | +$4.26M |
|
49
Absci
ABSI
$381M
| $3.98M | 0.2% |
+700,000
| New | +$3.98M |
|
50
Atara Biotherapeutics
ATRA
$85.1M
| $2.88M | 0.14% |
+166,000
| New | +$2.88M |
|